1. Home
  2. CRDL vs GMM Comparison

CRDL vs GMM Comparison

Compare CRDL & GMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDL
  • GMM
  • Stock Information
  • Founded
  • CRDL 2017
  • GMM 2017
  • Country
  • CRDL Canada
  • GMM China
  • Employees
  • CRDL N/A
  • GMM N/A
  • Industry
  • CRDL Biotechnology: Biological Products (No Diagnostic Substances)
  • GMM
  • Sector
  • CRDL Health Care
  • GMM
  • Exchange
  • CRDL Nasdaq
  • GMM Nasdaq
  • Market Cap
  • CRDL 80.1M
  • GMM 70.8M
  • IPO Year
  • CRDL N/A
  • GMM 2023
  • Fundamental
  • Price
  • CRDL $1.15
  • GMM $2.82
  • Analyst Decision
  • CRDL Strong Buy
  • GMM
  • Analyst Count
  • CRDL 3
  • GMM 0
  • Target Price
  • CRDL $9.00
  • GMM N/A
  • AVG Volume (30 Days)
  • CRDL 150.5K
  • GMM 55.9K
  • Earning Date
  • CRDL 05-20-2025
  • GMM 05-20-2025
  • Dividend Yield
  • CRDL N/A
  • GMM N/A
  • EPS Growth
  • CRDL N/A
  • GMM 62.17
  • EPS
  • CRDL N/A
  • GMM 6.37
  • Revenue
  • CRDL N/A
  • GMM $41,360,953.00
  • Revenue This Year
  • CRDL N/A
  • GMM N/A
  • Revenue Next Year
  • CRDL N/A
  • GMM N/A
  • P/E Ratio
  • CRDL N/A
  • GMM $0.42
  • Revenue Growth
  • CRDL N/A
  • GMM 53.82
  • 52 Week Low
  • CRDL $0.77
  • GMM $0.21
  • 52 Week High
  • CRDL $3.12
  • GMM $4.97
  • Technical
  • Relative Strength Index (RSI)
  • CRDL 57.19
  • GMM 54.98
  • Support Level
  • CRDL $1.02
  • GMM $2.13
  • Resistance Level
  • CRDL $1.19
  • GMM $2.64
  • Average True Range (ATR)
  • CRDL 0.07
  • GMM 0.26
  • MACD
  • CRDL 0.01
  • GMM 0.09
  • Stochastic Oscillator
  • CRDL 73.53
  • GMM 71.88

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About GMM Global Mofy Metaverse Limited

Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.

Share on Social Networks: